沙美特罗替卡松联合噻托溴铵与单用沙美特罗替卡松治疗我国慢性阻塞性肺疾病患者的Meta分析

发布时间：2018-03-15 22:24

  本文选题：噻托溴铵　切入点：沙美特罗替卡松　出处：《中国呼吸与危重监护杂志》2017年06期 　论文类型：期刊论文

【摘要】：目的 系统评价沙美特罗替卡松联合噻托溴铵与单用沙美特罗替卡松治疗我国慢性阻塞性肺疾病(简称慢阻肺)患者的有效性及安全性。方法 计算机检索PubMed、Embase、The Cochrane Library(2017年第4期)、CNKI、VIP和WanFang Data数据库,搜集沙美特罗替卡松联合噻托溴铵与单用沙美特罗替卡松治疗我国慢阻肺患者的相关随机对照试验(randomized controlled trials,RCT),检索时限均为从建库至2017年4月。由2位评价员按照纳入与排除标准独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果 共纳入30个RCT研究,3 121例患者。Meta分析结果显示:在有效性方面,与单用沙美特罗替卡松比较,沙美特罗替卡松联合噻托溴铵能有效改善慢阻肺患者的FEV_1[MD=0.30,95%CI(0.22,0.39),P0.000 01]、FVC[MD=0.31,95%CI(0.23.0.40),P0.000 01]及FEV_1/FVC[MD=9.07,95%CI(6.69,11.44),P0.00001];在安全性方面,两组不良反应发生率无明显差异[OR=1.17,95%CI(0.83,1.66),P=0.37]。结论 现有证据表明,应用噻托溴铵联合沙美特罗替卡松可改善我国慢阻肺患者的肺功能指标。受纳入研究数量和质量限制,上述结论尚需开展更多高质量研究予以验证。
[Abstract]:Objective to evaluate Shah Mette Lo and fluticasone propionate combined with tiotropium alone Shah Mette Lo Tikason Chinese treatment of chronic obstructive pulmonary disease (COPD) the efficacy and safety of patients. Methods we searched PubMed, Embase, The Cochrane Library (2017 fourth), CNKI, VIP and WanFang Data database, randomized controlled collect the test Shah Mette Lo fluticasone propionate combined with tiotropium alone with Shah Mette Lo Tikason in the treatment of Chinese patients with COPD (randomized controlled, trials, RCT) were searched from inception to April 2017. By 2 reviewers independently screened according to the inclusion and exclusion criteria of literature, extracted the data and assessed the risk of bias of included studies. Meta analysis was performed using RevMan 5.3 software. The results of the 30 RCT study included 3121 patients with.Meta, the results showed that: in terms of effectiveness, with Shah Mette Lo 鏇垮崱鏉炬瘮杈，

本文编号：1617110